GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Incannex Healthcare Ltd (STU:IQI) » Definitions » Price-to-Owner-Earnings

Incannex Healthcare (STU:IQI) Price-to-Owner-Earnings : 2.80 (As of May. 21, 2024)


View and export this data going back to 2011. Start your Free Trial

What is Incannex Healthcare Price-to-Owner-Earnings?

As of today (2024-05-21), Incannex Healthcare's share price is €0.028. Incannex Healthcare's Owner Earnings per Share (TTM) ended in Mar. 2024 was €0.01. It's Price-to-Owner-Earnings for today is 2.80.


The historical rank and industry rank for Incannex Healthcare's Price-to-Owner-Earnings or its related term are showing as below:

STU:IQI' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 0   Med: 0   Max: 2.06
Current: 2.06

During the past 13 years, the highest Price-to-Owner-Earnings of Incannex Healthcare was 2.06. The lowest was 0.00. And the median was 0.00.


STU:IQI's Price-to-Owner-Earnings is not ranked
in the Drug Manufacturers industry.
Industry Median: 28.05 vs STU:IQI: 2.06

As of today (2024-05-21), Incannex Healthcare's share price is €0.028. Incannex Healthcare's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was €-0.01. Therefore, Incannex Healthcare's PE Ratio for today is At Loss.

As of today (2024-05-21), Incannex Healthcare's share price is €0.028. Incannex Healthcare's EPS without NRI for the trailing twelve months (TTM) ended in was €-0.01. Therefore, Incannex Healthcare's PE Ratio without NRI for today is At Loss.

During the past 13 years, Incannex Healthcare's highest PE Ratio without NRI was 4.15. The lowest was 0.00. And the median was 3.20.


Incannex Healthcare Price-to-Owner-Earnings Historical Data

The historical data trend for Incannex Healthcare's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Incannex Healthcare Price-to-Owner-Earnings Chart

Incannex Healthcare Annual Data
Trend Jun13 Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22
Price-to-Owner-Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Incannex Healthcare Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 6.90 - - -

Competitive Comparison of Incannex Healthcare's Price-to-Owner-Earnings

For the Drug Manufacturers - Specialty & Generic subindustry, Incannex Healthcare's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Incannex Healthcare's Price-to-Owner-Earnings Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Incannex Healthcare's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Incannex Healthcare's Price-to-Owner-Earnings falls into.



Incannex Healthcare Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Incannex Healthcare's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=0.028/0.01
=2.80

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Incannex Healthcare  (STU:IQI) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Incannex Healthcare Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Incannex Healthcare's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Incannex Healthcare (STU:IQI) Business Description

Traded in Other Exchanges
Address
8 Century Circuit Norwest, Suite 105, Sydney, NSW, AUS, 3000
Incannex Healthcare Inc is a clinical stage pharmaceutical company developing medical cannabis products for the treatment of Obstructive Sleep Apnea (OSA), Traumatic Brain Injury (TBI)/Concussion, Rheumatoid Arthritis, Inflammatory Bowel Disease, and Inflammatory Lung Conditions. The company has an Australian license to import, export, and distribute medicinal cannabis products and has launched a line of cannabinoid products.